We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s Drug Safety Research Unit (DSRU), a nonprofit that studies the safety of medicines, has published the first benefit-risk analysis for Gilead Sciences’ antiviral remdesivir, finding that it has a favorable overall profile, although questions remain about the drug’s safety. Read More
AbbVie has entered into a partnership with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a monoclonal antibody therapy for COVID-19. Read More
A Texas study of convalescent plasma as a treatment for critically ill COVID-19 patients found the blood-based treatment to be safe for severely infected patients. Read More
AstraZeneca and Accent Therapeutics have teamed up to develop cancer therapies using RNA-modifying proteins in a deal potentially worth more than $1 billion for the small Massachusetts-based startup. Read More
The Lancet and the New England Journal of Medicine (NEJM) yesterday retracted separate studies of two different COVID-19 treatments because of concerns over the underlying data provided by the same data analytics company, Surgisphere. Read More
Researchers in the UK are launching a clinical trial to test a unique formulation of ibuprofen for treatment of severe acute respiratory distress syndrome (ARDS) in COVID-19 patients. Read More
Several common cardiovascular drugs are being studied as potential COVID-19 treatments, with early findings suggesting they pose no increased risks for patients taking them regularly. Read More
The London study will recruit hospitalized COVID-19 patients who will either receive the standard of care or ibuprofen in addition to standard of care. Read More